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REVIEW
Abstract: Restless legs syndrome (RLS) is a common condition that is frequently
unrecognized, misdiagnosed and poorly managed. It is characterized by uncomfortable
sensations deep in the legs developing at rest that compel the person to move; symptoms are
worst at night and sleep disturbance is common. RLS occurs in 7%–11% of the population in
Western countries, and many such people experience troublesome symptoms. Primary RLS
is familial in up to two thirds of patients. RLS may also be secondary to a number of conditions
including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy.
Secondary RLS is most common in those presenting for the first time in later life. The
pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and
impaired dopaminergic neurotransmission in the subcortex of the brain. RLS is very responsive
to dopaminergic therapies. Rebound of RLS symptoms during the early morning and
development of severe symptoms earlier in the day (augmentation) are problematic in those
treated for a prolonged period with levodopa. Consequently, dopamine agonists have become
first line treatment. Anti-convulsant medications and opioids are helpful in some patients.
Correction of underlying problem wherever possible is important in the management of
secondary RLS.
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Introduction
Restless Legs Syndrome (RLS) was first described in the medical literature by the
anatomist and physician Thomas Willis in 1685 and has been recognized as a well-
defined, common and frequently distressing entity since Ekbom’s classic description
in 1945. Nevertheless, RLS has attracted little attention in medical textbooks until
recently, and, even now, it is often unrecognized, misdiagnosed and poorly managed.
In this paper, we explore the reasons for the relative neglect of RLS, explain
current thinking regarding the pathogenesis and management of the condition and
show why patients with RLS will benefit from careful investigation and treatment.
What is RLS?
RLS is both a sensorimotor and a sleep disorder. It is characterized by unusual,
uncomfortable sensations deep in the legs (and sometimes arms) that compel the
person to move to relieve the sensation and that are brought on and exacerbated by
rest; symptoms are particularly troublesome in the evening and at night, and sleep
disturbance is common. The original report by Willis (1685) described the motor
features and the sleep disruption but did not mention the sensory features that are
often the main complaint of patients. In contrast, Karl-Axel Ekbom (1945) emphasized
the importance of the sensory component of the condition.
The current diagnostic criteria were developed at an National Institutes of Health
(NIH)-supported workgroup on RLS and represent a slight modification of the original
diagnostic criteria published by the International RLS Study Group in 1995 (Walters
1995; Allen et al 2003). There are four essential criteria and three supportive clinical
features (Table 1).
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The sensation is deep seated, often described as being
in the shin bones, and most commonly felt between the knee
and ankle. It may be described as a creepy, crawly, shock-
like, tense, electric, buzzing, itchy, or even numb sensation.
Bizarre analogies may be draw such as ‘worms under the
skin’ or ‘cola in the veins’. There is a variable response to
temperature, with some finding heat an aggravating factor
and removing the bedclothes, whilst others find that wearing
socks or taking a hot bath improves symptoms.
RLS patients not only feel an urge to move but, while
this may be resisted for a time, they must at some stage
actually yield to the urge and move the legs. This movement
should lead to immediate, even if sometimes only partial,
relief that persists while moving. Mild cases can get relief
from rubbing the legs or stretching them in the bed, but
people with more severe symptoms need to get out of bed
and walk, or stretch, or march on the spot.
There is always a strong circadian pattern to symptoms
in RLS. The peak is usually during the earlier part of the
night, but the precise timing will vary depending on the
sleep habits and the trough of circadian rhythm for the
individual. The rest-induced and circadian patterns of RLS
can be distinguished. Thus, symptoms during rest at night
are worse than symptoms at rest during the day.
There are a number of conditions that may be confused
with RLS. Akathisia is a closely related condition that shares
the sense of restlessness, the inability to sit still and, less
prominently, the sleep disturbances (Walters et al 1991).
However, the restlessness is generalized and internal rather
than localized to the limbs and associated with paresthesias.
The history of exposure to neuroleptic medications and
associated extrapyramidal features also differentiate
akathisia from RLS. Nocturnal leg cramps are characterized
by episodes of pain, usually lasting up to a few minutes,
caused by sudden, intense involuntary contractions of
muscles or muscle groups. Residual discomfort and
tenderness may persist for hours afterwards. They should
be readily distinguishable from RLS by history alone.
Polyneuropathy may lead to symptoms of burning in the
legs and feet at night. However, there is no restlessness and
no improvement with movement. Also, physical
examination in these cases will reveal a sensory and
occasionally motor deficit. Peripheral vascular disease can
result in rest pain at night, which should be readily
identifiable; clinical examination may demonstrate
ischaemic features in the leg. Painful legs and moving toes
is an uncommon condition associated with involuntary toe
movements and with pain in the legs that has a similar
distribution to that seen in RLS (Dressler et al, 1994). The
major difference is that the pain in the former is not relieved
by movement.
Why is RLS neglected?
RLS is often unrecognized or misdiagnosed. In a study
published in 1996 of patients who belonged to the ‘Night
Walkers’ support group, patients delayed seeking attention
for many years, but even after they sought medical help,
accurate diagnosis frequently took a decade or more (Walters
et al 1996). The expansion in knowledge and the increased
publicity about the condition in recent years seems to have
Table 1 Features of restless legs syndrome (RLS). Modified from Allen RP,  Picchietti D, Hening WA, et al. 2003. Restless legs
syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and
epidemiology workshop at the National Institutes of Health. Sleep Med Mar, 4:101-19.
A. Essential criteria: These features must be present for a diagnosis of RLS.
1. An urge to move the legs, usually accompanied or caused by uncomfortable or unpleasant sensations in the legs. (Sometimes the urge to move
 is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs.)
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the
 activity continues.
4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.
(When the symptoms are very severe, the worsening at night may not be noticeable, but must have been previously present.)
B. Supportive clinical features of RLS: Presence of these features may help resolve any diagnostic uncertainty.
1. Periodic limb movements (during wakefulness or sleep).
2. Family history of RLS in a first degree relative.
3. Response to dopaminergic therapy.
C. Associated clinical features: These features may provide additional information about the patient’s diagnosis.
1. Clinical course following certain identifiable patterns.
2. Sleep disturbance.
3. Normal medical evaluation/ physical examination.Therapeutics and Clinical Risk Management 2006:2(4) 467
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made little difference and has led to accusations of ‘disease
mongering’ (Woloshin and Schwartz 2006). An international
population study published in 2004 reported that two thirds
of those with weekly RLS symptoms said that they had
spoken to a physician about their symptoms and only 8%
said that they had received a diagnosis of RLS (Hening et
al 2004). A number of myths and misconceptions probably
contribute to this dismal situation.
Myth 1: RLS is a trivial condition
RLS is sometimes regarded as merely an inconvenience to
the sufferer or even as an entity with no physiological basis.
A number of factors may underlie this myth. The very name
of the condition sounds benign if not even slightly funny.
Few of us have not experienced the discomfort and urge to
move the legs that develops on a long, cramped journey,
and RLS may be regarded as a ‘natural’ phenomenon.
Clinicians may be sceptical, in particular, of the high
prevalence of RLS reported in epidemiological studies.
It is important to acknowledge that many people with
RLS have relatively mild symptoms, and it is doubtful
whether there is any benefit in telling such people that they
have a recognized medical condition. Nevertheless, there is
a substantial group of patients with symptoms of sufficient
severity to warrant intervention. Data from the RLS
Epidemiology, Symptoms and Treatment (REST) studies
conducted in the general population and in primary care
practices in the US and some European countries illuminate
this point (Hening et al 2004; Allen et al 2005). RLS of any
degree of frequency or severity occurred in 7.2% and 11.1%
of these studies respectively; RLS that occurred more than
twice a week and that caused significant distress was present
in roughly a third of each group (2.7% and 3.4%
respectively). Also, even those with mild symptoms may
benefit from being given a diagnosis to explain their unusual
symptoms.
It is also true that RLS does not pose the same threat to
health as does heart disease or diabetes, for example.
Nevertheless, as will be shown later, it may have a very
significant effect on the quality of life of the sufferer, and
the chronic insomnia in particular may impact on daytime
functioning.
Myth 2: RLS is ‘all in the head’
Many sufferers report that they have been told their
symptoms are psychogenic. Richard Allen (personal
communication) tells of one patient who was referred for
five years of psychoanalysis as doctors were convinced that
he was kicking his wife at night because he was angry at his
mother! The difficulty that RLS patients often experience
in describing the nature of their leg sensations, and the
sometimes bizarre analogies they draw, may contribute this
misconception. Patients may also delay presenting for
medical attention because they fear they will not be
believed.
It is undeniable that RLS is associated with anxiety and
depression (Picchietti and Winkelman 2005). In a study from
Munich, RLS patients were compared with patients with
other chronic disorders (Winkelmann et al 2005). There was
a much higher prevalence in the RLS group of panic disorder
(odds ratio [OR] of 4.7), of generalized anxiety disorder
(OR 3.6) and of major depression (OR 2.7). Also, the RLS
patients were more likely to attribute their psychiatric
disorders and associated symptoms directly to the impact
of their underlying condition on their life. The association
with depression also has practical significance for the
management of RLS; serotonin reuptake blocking
antidepressants and, less often tricyclic antidepressants, can
precipitate or exacerbate symptoms of RLS (Dorsey et al
1996). Bupropion, an antidepressant with dopamine agonist
activity, may be a useful alternative (Nofzinger et al 2000).
Myth 3: RLS is ‘all in the legs’
The notion that RLS is due to a vascular disorder of the
legs, especially of the veins, dates back to Ekbom (1945)
and persists to some degree today (Kanter 1995).
Examination of peripheral arteries and veins is normal in
most RLS patients. Procedures to reduce incompetent veins
have not been shown to reduce RLS symptoms (Kanter
1995; Bradbury et al 1999).
The role of peripheral neuropathy in the pathogenesis
of RLS is less clear cut. It has been reported that RLS may
be a presenting feature of neuropathy, such as those due to
diabetes mellitus, alcohol abuse, Charcot-Marie-Tooth
syndrome type 2, and of spinal disease such as radiculopathy
(Ondo and Jankovic 1996; Gemignani et al 1999). Also,
detailed evaluation of RLS patients with sural nerve or skin
biopsies has found a high frequency of clinically
undetectable axonal and small-fiber neuropathies (Polydekis
et al 2000). However, other studies have suggested that the
frequency of RLS in neuropathic patients is similar to that
in the general population (Salih et al 1994; Banno et al 2000).
Nevertheless, as will be discussed later, most evidence points
to a central nervous system abnormality.Therapeutics and Clinical Risk Management 2006:2(4) 468
Cotter and O’Keefe
Myth 4: There is no good treatment for
RLS
A degree of therapeutic nihilism may have been justified in
the past but is inexcusable with the emergence, in particular,
of dopaminergic treatments for RLS. Unfortunately, many
clinicians persist in using benzodiazepines, which, while
sometimes effective, often cause unacceptable side effects.
Others, perhaps misdiagnosing RLS as related to muscle
cramps, use quinine, which has been shown to be ineffective
in RLS (Van Dijk et al 1991).
Why is RLS an important
condition?
RLS is an important condition because it is common, it
causes significant distress to sufferers, it may be the
presenting feature of serious underlying conditions and it is
treatable. In recent years, there has been an improved
understanding of the pathophysiology of the condition,
particularly in relation to genetic susceptibility and to the
importance of dopamine and of iron metabolism.
RLS is common
Ekbom performed the first study on the prevalence of RLS
and reported that about 5% of a middle aged Swedish
population had the condition (Ekbom 1945). However,
interpretation of this and subsequent studies up to 1995 were
hampered by the lack of agreed diagnostic criteria for the
condition. Since then a substantial number of studies have
been conducted, mainly in European and North American
populations, using questions designed to elicit the essential
criteria of the condition and usually requiring some
minimum frequency of symptoms. As a general rule, slightly
higher rates are found in studies based on self-administered
questionnaires compared with studies using face-to-face or
telephone interviews; the latter studies are probably more
reliable. Allowing for differences in study designs and in
the age and sex profile of the populations studied, there has
been a remarkable consistency across different studies, with
prevalence rates ranging from approximately 5% to 15%.
Indeed more recent studies have converged on a range of
7%–11%. For example, a large recent French study,
involving face-to-face interviews of 10 238 individuals,
found a prevalence of RLS symptoms of 8.5% with a narrow
confidence interval of ± 0.5% (Tison et al 2005) (Table 2).
An increase in symptoms with age has been reported in
most studies. For example, in an American study, Phillips
and colleagues (2000) asked 1803 men and women on the
telephone if they experienced symptoms of restless legs 5
or more nights per month. They received a positive response
in 3% of participants aged 18 to 29, 10% aged 30 to 79
years and 19% of those aged 80 years and older. In recent
years, there is increased recognition that RLS may also
present during childhood; the condition may be
misdiagnosed as attention-deficit/hyperactivity disorder or
as ‘growing pains’ (Kotagal and Silber 1999).
Another striking finding, originally reported by Ekbom
(1945), is the increased frequency of the condition in women
compared with men, with a two-fold difference in some
reports (Rothdach et al 2000; Egan et al 2003). Associations
that have been reported in population studies include links
to psychiatric disorders, general health, smoking, body mass
index, lower socioeconomic status, diabetes, lack of
exercise, and alcohol abstinence (Phillips et al 2000).
The relatively few studies in non-European populations
suggest that RLS may be less common in such populations.
A Turkish study found a prevalence of 3%, while a study in
Singapore found that less than 1% of those questioned
reported RLS symptoms (Sevim et al 2003). A Japanese
study found that 1.1% reported RLS symptoms; however,
contrary to the pattern in Europe, symptoms were more
common in men. On the other hand, a recent Korean study
Table 2 Epidemiological studies of the prevalence of Restless
Legs Syndrome using International Restless Legs Syndrome
(IRLS) Study Group criteria and either telephone or face-to-
face interviews
Year Author n Population Prevalence
1994 Lavigne and 2019 Canada, 10%
Montplaisir
*
2000 Phillips et al** 1803 Kentucky, USA 10.0%
2000 Rothdach et al 369 Germany, 9.8%
65–83 years
2002 Ohayon and 18 980 Five European 5.5%
Roth countries
2003 Sevim et al 3234 Turkey, 3.2%
2005 Allen et al 15 391 USA, 5 European 7.2%
countries,
2005 Högl et al 701 Bruneck, 10.6%
Northern Italy,
40–79 y
2005 Bjorvatn et al 2005 Norway and 11.5%
Denmark,
2005 Mizuno et al† 3287 Japan >65 years 1.1%
2005 Tison et al 10 263 France, adults 8.5%
2005 Kim et al 9930 Korea, adults 12.1%
Notes: 
*3 of 4 IRLS criteria used for diagnosis; 
**2 of 4 IRLS criteria used for
diagnosis; 
†Screening by questionnaire, followed by telephone interview.Therapeutics and Clinical Risk Management 2006:2(4) 469
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reported RLS in 12% of those studied and found a higher
prevalence in women and in older people (Kim et al 2005).
RLS can cause significant distress
Severe RLS is a deeply unpleasant condition. In a study of
the impact on quality of life of sufferers (using the Short
Form-36 Health Survey), RLS had a similar effect to other
chronic disorders, such as type 2 diabetes, and clinical
depression (Allen et al 2005). RLS may require a
considerable restriction of lifestyle as a result of intolerable
symptoms during long airplane or car journeys, lectures or
visits to the cinema.
One or more aspects of the condition may be particularly
troublesome for individual patients. As part of the REST
primary care study, 182 patients with RLS were asked about
their symptoms (Hening et al 2004). The most troublesome
symptoms reported were sleep disturbance (39%), followed
by uncomfortable feelings in the legs (27%), pain (22%)
and inability to stay still and urge to move the legs (11%).
Thus, sleep disturbance, subsequently causing
disturbance of day-time functioning in many, are of
particular significance to RLS patients. This is not surprising
since severe RLS produces the most extreme chronic sleep
loss of any sleep disorder. There are multiple reasons for
this. In the REST study, almost 70% of sufferers reported a
sleep latency (the time to get to sleep) of 30 minutes or
longer, which is considered to be in the insomnia range. On
a poor night, 50% reported less than 5 hours sleep and 14%
got less than 3 hours sleep. Almost 60% reported that they
wake three or more times a night so that sleep is significantly
fragmented. Other daytime symptoms reported by patients
included fatigue in 60% and difficulty concentrating in 50%.
However, RLS patients do not report the same degree of
daytime sleepiness or the risk of accidents that have been
found, for example, in the sleep apnoea population. This
may be due to the restlessness, with arousal and activity,
intrinsic to the condition.
The fragmentation of sleep may result from the RLS
itself or from accompanying periodic limb movements of
sleep (PLMS) (Trenkwalder, Walters, et al 1996). PLMS
are semirhythmic movements of the limbs which last a few
seconds and occur at regular intervals. The most frequent
movement seen is dorsiflexion of the great toe (similar to
the Babinski response), with flexion of the knee, hip, and
occasionally elbow. PLMS can occur in otherwise healthy
people and are especially common in old age. In RLS, they
are almost always present, are often very intense and can
cause arousals and awakenings. Some RLS patients do not
get symptoms until they have been asleep for a while; they
wake up, perhaps because of the PLMS, and develop the
fidgety sensations of RLS and have to get up and walk for a
while before they can return to sleep.
RLS is a chronic disorder. In the Hopkins family study,
the average duration of symptoms in 66 RLS patients was
30 years (n=66) (Allen et al 2002). In general, symptoms
tend to progress with advancing age, although there is
considerable individual variability.
RLS may be symptomatic of an
underlying condition
RLS can generally be divided into primary and secondary
forms. RLS is primary (idiopathic) in most cases, and up to
half of these patients have a positive family history
(Trenkwalder, Seidel, et al 1996). RLS may also develop
secondary to a variety of conditions, although, since RLS is
a common condition, many of the associations suggested
by case reports remain unproven. Secondary causes of RLS
are more common in those who develop the condition for
the first time in later life, occurring in over 70% of those
with onset at 65 years or more, while a positive family seems
most common those with early-onset RLS (O’Keeffe 2005).
Genetics of RLS
The mode of inheritance of RLS seems to be autosomal
dominant. There is a high concordance rate (83%) for RLS
symptoms in monozygotic twins (Ondo et al 2002) although
expression of RLS can vary between twins and within
families. Age-dependent penetrance of RLS has been
reported, with full penetrance by the age of 60 (Winkelmann
2002). Anticipation, an earlier age of onset in later
generations, has also been reported (Trenkwalder, Seidel,
et al 1996). Susceptibility loci have been described on
chromosome 12q in a French-Canadian family (Desaultels
et al 2001), on chromosome 14q in an Italian family (Bonati
et al 2003) and on chromosome 9p in North American
families (Chen et al 2004). It seems increasingly likely that
multiple genes influence the development of RLS, perhaps
interacting with environmental factors.
Secondary RLS
The most important secondary form of RLS is the association
with iron deficiency (with or without anemia) which is
present in up to a third of RLS patients (Ekbom 1960;
O’Keeffe et al 1993), including those presenting in
childhood pains (Kotagal and Silber 1999). Serum ferritin
is accepted as the best screening test for iron deficiency,Therapeutics and Clinical Risk Management 2006:2(4) 470
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and in older hospital patients, the diagnosis of iron
deficiency is almost certain in those with ferritin less than
20 ng/mL and is likely in those with levels less than 50 ng/
mL. The severity of RLS symptoms correlates well with
the serum ferritin level, even in patients who are not
obviously iron deficient and who have normal hemoglobin
and MCV levels (O’Keeffe et al 1994). A search for an
underlying cause of iron deficiency is usually indicated and
may lead to the detection of new cancers (Brocklehurst 2003;
O’Keeffe 2005).
RLS has been noted in 15% to 40% of patients with
end-stage renal disease; it is particularly prominent in
patients on hemodialysis, possibly because of the enforced
rest (Collado-Seidel et al 1998). RLS is also common during
the third trimester of pregnancy and resolves after delivery
(Lee et al 2001). Development of transient RLS during
pregnancy may suggest a predisposition to develop the
condition in later life (Ulfberg et al 2001; Berger et al 2004).
There is also good evidence to support associations between
RLS and rheumatoid arthritis and Sjogren’s syndrome
(Reynolds et al 1986; Gudbjornsson et al 1993; Salih et al
1994). As was noted earlier, the relationship between RLS
and peripheral neuropathy is unclear. There have also been
conflicting reports regarding a possible association between
RLS and Parkinson’s disease (PD) are associated (Garcia-
Borreguero et al 2003). A recent study noted that 21% of
PD patients had RLS, with lower ferritin levels being the
main predicting factor for development of RLS (Ondo et al
2002). Disturbance of iron metabolism may also influence
the relationships between RLS and conditions such as
uremia, pregnancy, and rheumatoid arthritis.
Thus, physicians faced with a patient with RLS should
inquire about factors predisposing to iron deficiency,
including menorrhagia in premenopausal women, coeliac
disease, gastrointestinal and urinary blood loss, and frequent
blood donation. Full blood count to exclude anemia, serum
ferritin and transferrin saturation, serum urea and creatinine
and blood glucose should be performed, at a minimum. With
symptoms or physical findings suggestive of nerve root
damage or neuropathy, the patient should be evaluated for
neuropathy and for factors contributing to neuropathy.
Iron–dopamine hypothesis
The improvement in RLS with dopaminergic agonists and
the worsening of symptoms with dopaminergic antagonists
that cross the blood–brain barrier, combined with the lack
of effect of the dopamine antagonist domperidone, which
does not cross the blood–brain barrier, suggest an important
role for the dopamine neurotransmitter system in the central
nervous system in the pathogenesis of RLS. Positron
emission tomography and single photon emission computed
tomography studies have found a decreased activity of the
dopamine D2-receptor in the striatum in RLS, consistent
with a role for a subcortical dysfunction of the
dopaminergic system in RLS (Turjanski et al 1999;
Michaud et al 2002).
Reflex studies suggest that RLS involves increased
(rather than the normal decreased) spinal cord excitability
with sleep, probably due to impaired subcortical regulation
of spinal function (Bara-Jimenez et al 2000; Aksu and Bara-
Jimenez 2002). Functional MRI studies showing activation
of the thalamus and cerebellum during sensory events
(without movements), and of the pons and red nucleus
during sensory events that were accompanied by movements
in RLS are also consistent with subcortical dysfunction
(Bucher et al 1997). The dopaminergic A11 cell group is
postulated as being centrally involved as they are the only
neurones which provide dopaminergic axons to the spinal
cord; lesions of the subcortical A11 dopamine system in
rats produces increased startle response and increased
locomotion, possibly suggesting the motor restlessness of
RLS (Ondo, He, et al 2000).
Iron is an essential cofactor for tyrosine hydoxylase, the
rate-limiting enzyme for dopamine synthesis. In animal
studies, iron deficiency is associated with hypofunction of
dopamine D2 receptors that is corrected by iron replacement
(Erikson et al 2003; Burhans et al 2005). The fact that the
established secondary causes of RLS share disturbance of
iron metabolism as a common feature, that the degree of
iron deficiency correlates well with symptoms, and that iron
is an effective therapy, at least in iron-deficient patients
provide clinical support for the importance of iron deficiency
in the pathogenesis of RLS. Further support comes from
cerebrospinal fluid analysis of iron indices suggesting brain
iron deficiency (Earley et al 2000), and from magnetic
resonance imaging (MRI) (Allen et al 2001) and autopsy
findings of regional basal ganglia iron deficiency (Connor
et al 2004).
Thus, the current hypothesis is that RLS involves a
functional disturbance of dopamine neurotransmission in
subcortical areas of the brain, provoked by regional iron
deficiency or by genetic factors or both, resulting in
decreased inhibition of the sensorimotor cortical system and
(particularly during sleep) of the spinal system.Therapeutics and Clinical Risk Management 2006:2(4) 471
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RLS is treatable
Non-pharmacological measures
There are now a number of proven, effective therapies for
RLS. However, the first issue for the clinician is whether or
not pharmacological therapy is required. Non-
pharmacological measures should be considered first in all
but the most severe of cases. These included regular exercise,
and improved sleep hygiene with regular sleep wake cycle
and avoidance of alcohol, nicotine, and caffeine (Thorpy
2005). Patients may already have identified measures that
they find helpful in preventing or ameliorating RLS
symptoms. These may include physical activity such as
stretching exercises just before bedtime; hot or, less often
cold baths before bedtime; and mental activities that occupy
them such as video games, conversation or even knitting.
Nicotine, caffeine, alcohol, many antidepressants,
antihistamines, most antinausea agents, and most
antipsychotics have the potential to increase RLS symptoms
or PLMS and should be avoided if possible.
Pharmacotherapy: general principles
Finding the best treatment for an individual patient usually
proceeds in a ‘hit and miss’ fashion. Medications should be
used at the lowest effective dose, and when necessary the
dose should be titrated upward slowly. Medication should
be given early enough to allow absorption and action before
the onset of sleep; divided doses are often needed, most
commonly with the evening meal and later at night. If the
first agent does not work, then a second agent with a different
mode of action should be substituted; sometimes a
combination of medications works better than any single
agent.
Table 3 summarizes the double-blind randomized
controlled trials reported to date. Many of the initial studies
were small crossover trials, and it is only in recent years
that relatively large scale studies have been conducted.
Dopaminergic therapy
Akpinar’s (1982) discovery that levodopa was dramatically
effective in RLS revolutionized the management of RLS.
Subsequently, every dopaminergic agent tested has been
found to be effective against RLS and PLMS. Levodopa
(with a dopa decarboxylase inhibitor) provides a remarkable
near-immediate relief from RLS; this response is so
characteristic that a brief trial of levodopa may be considered
for patients in whom the diagnosis of RLS is in doubt (Benes
et al, 1999). Levodopa is also extremely effective in
haemodialysis patients with RLS (Trenkwalder et al 1995).
In general, levodopa is very well tolerated. Levodopa-
induced dyskinesias have never been found in RLS patients.
Studies with 18F-fluorodopa PET showing normal nigro-
striatal binding capacities after more than 5 years of
treatment in patients with RLS provide further confirmation
of the safety of levodopa in this regard (Ruottinen et al
2000).
Unfortunately, two troublesome and common problems
develop with the prolonged use of levodopa and limit the
value of this otherwise almost ideal agent for RLS: rebound
and augmentation. Rebound is a consequence of the short
half-life of levodopa; after a while, patients start to wake
up at 4 AM or 5 AM with recurrence of their RLS. Addition
of a sustained release preparation can delay the onset of
rebound until later in the morning, although the long-term
efficacy of this approach is not well established (Collado-
Table 3 Medications shown to benefit idiopathic restless legs
syndrome (RLS) in randomized double blind trials
Medication Starting – usual dose Evidence
base
Dopamine precursors
Levodopa +/- 50–200 mg at night 3 RCTs,
benserazide 58 pts
Combined slow 100–200 mg at night 2 RCT
and regular release 51 pts
levodopa
Dopaminergic agonists
Pergolide 0.025–0.5 mg daily 3 RCTs
146 pts
Pramipexole 0.125–1.5 mg daily 2 RCTs
355 pts
Ropinirole 0.25–3.0 mg daily 4 RCTs
595 pts
Cabergoline 0.5–2.0 mg daily 1 RCT
85 pts
Rotigotine (patch) 1.125–4.5 mg daily 1 RCT
63 pts
Sedative-hypnotic agents
Clonazepam 0.25–2 mg at night 1 RCTs
6 pts
Antiepileptic agents
Carbamezapine 100–300 mg daily 1 RCT
174 pts
Gabapentin 300–1500 mg daily 1 RCTs
24 pts
Opioids
Oxycodone 5–20 mg daily 1 RCT
11 pts
Abbreviations: RCT, randomized controlled trials; pts, patients.Therapeutics and Clinical Risk Management 2006:2(4) 472
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Seidel et al 1999). Augmentation is a more serious problem.
This phenomenon has a number of components: symptoms
develop at an earlier time in the day; they may become more
severe; there may be a reduced time at rest to onset of
symptoms; finally, symptoms may develop in parts of the
body that were not previously involved such as the arms.
Up to 80% of patients treated with levodopa have some
augmentation symptoms after a few months, and about a
third have sufficiently severe symptoms that a change in
therapy is required (Allen and Earley 1996). For this reason,
levodopa is no longer the treatment of choice for RLS,
although it remains valuable for those with only
intermittently severe symptoms.
Dopamine agonists are now regarded as the first-line
treatment for RLS. The non-ergot agonists pramipexole,
ropinirole and rotigotine, as well as the ergot derived
cabergoline and pergolide, have all been shown to benefit
RLS in randomized controlled trials (Table 3).
Open label studies suggest that dopamine agonists are
well tolerated in patients with severe RLS who
 have failed
other therapies and also in those with augmentation (Stiasny,
Wetter, et al 2000). However, while initial reports using
pramipexole suggested that augmentation was very
uncommon with this agent, a recent study of prolonged
treatment has suggested levels of augmentation and
tolerance of 32% and 46% respectively (Winkleman and
Johnston 2004). These levels are still much lower than seen
with levodopa, though they seem more likely to occur in
those patients who previously developed similar problems
with levodopa. Dose modification may be required if
augmentation or tolerance develop, but, unlike the
situation with levodopa, a change in medication is rarely
needed.
The largest clinical trials to date have been conducted
using ropinirole. In two 12-week multinational studies,
ropinirole significantly improved RLS symptoms, associated
sleep disturbance and quality of life of RLS patients and
was generally well tolerated (Trenwalder et al 2004; Walters
et al 2004). Augmentation was not seen during the study
periods. However, the differences in symptom improvement
between placebo and ropinirole did not attain the pre-
determined clinically significant difference. Two factors may
be of relevance: a large placebo response has present in
both studies and the international RLS rating scale used as
a primary outcome may have been insufficiently responsive
to change.
Other medications
Antiepileptic agents
Carbamazepine 100–400 mg at night has been shown in
randomized trials to be effective in relieving paresthesias
and in reducing the number of attacks of RLS (Telstad et al
1984). However, side effects were very common, and,
increasingly, gabapentin, which is also effective but seems
better tolerated, is preferred (Garcia-Borreguero et al 2002).
Antiepileptic agents may have a particular role in patients
with painful paraesthesias or an underlying neuropathy. In
general, RLS can be treated with much smaller dosages than
are required to control seizures.
Opioids
Opioids were described as useful in the treatment of RLS
by Willis. Oxycodone has been proven in a small controlled
study to give symptomatic improvement and to reduce
PLMS (Walters et al 1993). There is, of course, the risk of
dependence with this class of medication, and they should
be avoided in those with a history of addiction. Nevertheless,
opioids retain a role in the treatment of particularly refractory
cases of RLS (Walters et al 2001). .
Benzodiazepines
Clonazepam was effective in a double-blind crossover study
of 6 RLS patients (Montagna et al 1984). It is likely that the
main effect of benzodiazepines in this population is mediated
by sleep promotion (Saletu et al 2001). Given the very
limited evidence of benefit and the risks of sedation and
falls, these agents should usually be avoided in RLS.
Treatment of secondary RLS
The management of the secondary causes of RLS involves
correction of the underlying problem where possible.
Treatment of iron deficiency, with or without anemia,
by oral iron supplements has been reported to improve or
resolve RLS symptoms. The benefit seems most clear cut
in those with almost certain iron deficiency, as indicated by
a serum ferritin less than 20 mcg/L. However, even those
with probable iron deficiency, and a serum ferritin between
20 mcg/L and 50 mcg/L may also benefit from iron
supplements; hence, the current recommendation to maintain
a serum ferritin greater than 50 mcg/L in RLS patients. There
seems little benefit from oral iron in those with ferritin levels
more than 50 mcg/L (Davis et al 2000). Standard treatment
is ferrous sulphate 325 mg daily, with or without vitamin C,Therapeutics and Clinical Risk Management 2006:2(4) 473
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taken on an empty stomach. There is recent evidence that
RLS and hereditary hemochromatosis can coexist
(Shaughnessy et al 2005), and ferritin and transferrin
saturation levels should be monitored while taking iron.
Potential benefits from intravenous iron therapy, even in
those without systemic iron deficiency, were suggested by
a study in the 1950s (Nordlander 1953) and is currently the
subject of investigations.
Randomized trials have demonstrated the efficacy of
levodopa (Trenkwalder et al 1995), pergolide (Pieta et al
1998), ropinirole (Pellecchia et al 2004) and gabapentin
(Thorp et al 2001) in uremic patients or in those undergoing
hemodialysis. Such patients are also reported to benefit from
intravenous iron therapy and from successful transplantation
(Sloand et al 2004).
The treatment of RLS in pregnancy is complicated by
the unsuitability of most of the available medications and
nonpharmacological methods should be encouraged.
Treatment of iron deficiency seems reasonable, but has never
been evaluated. Lower folate levels are associated with RLS
during pregnancy (Lee et al 2001). Folate supplementation
is now standard advice for those planning pregnancy;
compliance with this advice should be checked, and folate
levels assessed if necessary.
Treatment summary
In patients with regular, troublesome RLS symptoms, a
dopamine agonist is the current treatment of choice, although
it should be noted that there have been few satisfactory
studies comparing different treatment modalities for RLS.
If dopamine agoints are poorly tolerated or ineffective,
gabapentin or oxycodone should be considered. .
Levodopa is an excellent option for those with
intermittent symptoms, such as during a long trip or meeting.
It takes only 15 to 20 minutes to become effective, and
augmentation is not a risk with infrequent use.
Gabapentin or an opioid are reasonable choices where
RLS symptoms are painful or where there is coexisting
peripheral neuropathy.
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